Filing Flows › Aligos Therapeutics (ALGS) › Q3 2026
Aligos Therapeutics (ALGS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Aligos Therapeutics (ALGS) reported revenue of $2.8M for the third quarter 2026 (Q3 2026), +282% from a year earlier. Operating margin was -773.5%, net loss $21.9M (772.4% of revenue).
Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | — | +282% |
| Operating profit | −$21.9M | — | — |
| Net earnings | −$21.9M | — | — |
| Operating cash flow | $1.5M | — | — |
What changed
Revenue was $2.8M in Q3 2026, up 282% year over year.
Operating costs exceeded revenue by $21.9M, an operating margin of -773.5%. Total costs fell 15% while revenue rose 282%. The fastest-growing cost line was General & admin (+14%). The quarter ended with a net loss of $21.9M.
Operating cash flow was $1.5M. Non-cash charges added back $300K of depreciation and $1.3M of share-based compensation. Working capital and other items added $21.7M.
Questions
What was Aligos Therapeutics' revenue in the third quarter 2026?
Aligos Therapeutics (ALGS) reported revenue of $2.8M for the third quarter 2026 (Q3 2026), +282% from a year earlier.
Was Aligos Therapeutics profitable in the third quarter 2026?
Operating loss was $21.9M (-773.5% of revenue) and net loss $21.9M.